Kisspeptin Research Guide Ireland

Overview

Kisspeptin is an endogenous neuropeptide and the principal agonist of KISS1R (also known as GPR54), a G-protein coupled receptor. Kisspeptin neurons, located primarily in the arcuate nucleus and anteroventral periventricular nucleus of the hypothalamus, are now understood to be the master regulators of the hypothalamic-pituitary-gonadal (HPG) axis, sitting upstream of gonadotropin-releasing hormone (GnRH) neurons. Kisspeptin is not an approved medicine anywhere in the world and remains an investigational research compound. What sets it apart from many other research peptides is the unusually large body of real human clinical research behind it — particularly work conducted at Imperial College London — despite its purely investigational regulatory status. This guide summarises kisspeptin strictly as a research compound; it is not licensed by the HPRA in Ireland or by any equivalent regulator elsewhere for therapeutic use.

Clinical & Research Status

Evidence Type	Status
Human RCT	✔
Observational	✔
Animal Studies	✔
In Vitro	✔
Regulatory Approval	✗

Mechanism of Action

Kisspeptin neurons in the hypothalamus — chiefly in the arcuate nucleus and anteroventral periventricular nucleus — release kisspeptin peptides which bind to KISS1R (GPR54) receptors expressed on GnRH neurons. This binding triggers pulsatile release of GnRH, which in turn stimulates the anterior pituitary to secrete luteinising hormone (LH) and follicle-stimulating hormone (FSH). These gonadotropins then act on the gonads to drive sex steroid production and gametogenesis. Because of this position at the very top of the HPG axis, kisspeptin signalling is considered central to the onset of puberty and to the maintenance of normal reproductive function in adulthood. Research has also identified a mechanistic caveat: continuous, non-pulsatile high-dose exposure to kisspeptin can desensitise KISS1R, blunting the downstream LH response — an important consideration when interpreting dosing protocols used in human research.

Research Areas & Reported Effects

Reproductive Endocrinology and Fertility Research

The best-established human research application of kisspeptin is in assisted reproduction. Work from the Imperial College London group led by Professor Waljit S. Dhillo has investigated kisspeptin-54 as an alternative trigger for oocyte maturation during IVF, in place of hCG or GnRH agonist triggers, with the specific aim of reducing the risk of ovarian hyperstimulation syndrome (OHSS) in women at high risk.

Hypothalamic Amenorrhea and GnRH Pulsatility

Kisspeptin administration has been studied for its ability to restore pulsatile LH secretion in women with functional hypothalamic amenorrhea, a condition in which HPG axis signalling is suppressed, often in the context of low energy availability. Related research has also examined kisspeptin's effects on GnRH/LH pulsatility in men with hypogonadotropic hypogonadism.

Psychosexual and Emotional Processing Research

Comninos AN and colleagues at Imperial College London have used functional MRI to study kisspeptin's effects on brain activity related to sexual and emotional processing, including brain responses to visual and olfactory cues of attraction, pointing to a role for the peptide beyond simple gonadotropin regulation.

Puberty Onset Research

Because kisspeptin/KISS1R signalling is now understood to be a key trigger for the onset of puberty, research groups including those associated with Chan YM and colleagues have investigated its role in disorders of pubertal timing, including precocious and delayed puberty, as a way of better understanding the underlying hypothalamic mechanisms.

Research Data Summary

Study / Model	Reported Effect
Dhillo WS et al. healthy men study	Kisspeptin administration stimulated significant gonadotropin (LH) release in healthy male volunteers, confirming activity of the kisspeptin-GnRH axis in humans.
Jayasena CN et al. IVF trigger study	Kisspeptin-54 successfully triggered oocyte maturation in women at high risk of OHSS undergoing IVF, with a favourable safety profile compared to standard hCG triggers.
Comninos AN et al. fMRI study	Kisspeptin administration enhanced brain activity in regions associated with processing of sexual and romantic visual/olfactory stimuli in men.
George JT et al. hypothalamic amenorrhea study	Kisspeptin restored pulsatile LH secretion in women with hypothalamic amenorrhea, supporting its role in reproductive axis reactivation.
Continuous infusion research models	Prolonged continuous (non-pulsatile) kisspeptin exposure was associated with desensitisation of KISS1R and a blunted downstream LH response, in contrast to pulsatile dosing.

Stack Combinations Studied

• Kisspeptin-54 + hCG (comparative IVF trigger research) → Research rationale: Studied head-to-head as alternative oocyte maturation triggers, with kisspeptin-54 investigated specifically for its potential to reduce OHSS risk relative to standard hCG triggering.
• Kisspeptin + GnRH pulsatility studies → Research rationale: Used in combination with exogenous GnRH protocols in research settings to map the interaction between upstream kisspeptin signalling and downstream pituitary gonadotropin release.

⚠️ Stack combinations listed for research reference only. Not safety or efficacy guidance.

Research Protocol Reference

experimental research protocols only — not dosing recommendations.

Protocol	Dose (experimental model only)	Duration (experimental model only)	Frequency (experimental model only)	Research Context
Acute Bolus Research Protocol (KP-10)	Low microgram/kg range, single bolus	Single-dose study	Once	Acute LH pulsatility and gonadotropin response studies in healthy volunteers.
IVF Trigger Research Protocol (KP-54)	Fixed research dose (µg/kg, per Imperial College London trial designs)	Single administration	Once, at trigger stage	Oocyte maturation trigger studies in women at high OHSS risk.
Continuous Infusion Research Protocol	Low-dose continuous infusion	Hours (research infusion studies)	Continuous	Investigating receptor desensitisation and pulsatility mechanics.

Observed Side Effects in Research

• Mild injection site reactions
• Flushing
• Occasional nausea
• Theoretical KISS1R desensitisation with continuous high-dose exposure, blunting LH response

Kisspeptin has generally been well tolerated at research doses used in human trials, with no serious adverse events consistently reported in the published literature.

Compound Data

CAS Number

274901-16-5 (Kisspeptin-10)

Molecular Formula

C₆₃H₈₃N₁₇O₁₄ (Kisspeptin-10)

Molecular Weight

Approximately 1302.4 g/mol (Kisspeptin-10)

Half-Life

Very short (minutes) for Kisspeptin-10; longer (tens of minutes) for the full-length Kisspeptin-54 form

Synonyms

Metastin (original name for the 54-amino-acid form), KISS1-derived peptide, Kisspeptin-54/-14/-13/-10 (fragment forms)

Research Classification

KISS1R (GPR54) agonist, endogenous neuropeptide, HPG-axis regulator

Scientific References

• [Dhillo WS et al. 2005] — Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. — Journal of Clinical Endocrinology & Metabolism — [Human RCT]
• [Jayasena CN et al. 2014] — Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. — Journal of Clinical Investigation — [Human RCT]
• [Comninos AN et al. 2017] — Kisspeptin modulates sexual and emotional brain processing in humans. — Journal of Clinical Investigation — [Human RCT, fMRI]
• [George JT et al. 2011] — Kisspeptin-10 stimulates gonadotropin release in women with hypothalamic amenorrhea. — Journal of Clinical Endocrinology & Metabolism — [Human RCT]
• [Chan YM et al. 2011] — Kisspeptin resets the hypothalamic GnRH clock in men. — Journal of Clinical Endocrinology & Metabolism — [Human Study]

*This compliance check is automated and does not constitute legal advice. No Nonsense Fitness recommends independent legal review for all published content.*